Revisiting Immunotherapy in Tuberculosis
Debapriya Bhattacharya, Ved Prakash Dwivedi and Gobardhan Das*
Department of Medical Microbiology, DDMRI Building, Nelson R Mandela Medical School, University of KwaZulu-Natal, Durban, South Africa
- Corresponding Author:
- Gobardhan Das
Department of Medical Microbiology
Nelson R Mandela Medical School
University of KwaZulu-Natal, Durban, South Africa
E-mail: [email protected]
Received Date: November 27, 2013; Accepted Date: November 27, 2013; Published Date: December 04, 2013
Citation: Bhattacharya D, Dwivedi VP, Das G (2013) Revisiting Immunotherapy in Tuberculosis. J Mycobac Dis 4:e123. doi:10.4172/2161-1068.1000e123
Copyright: © 2013 Bhattacharya D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The World Health Organization (WHO) estimates that one third of the global population is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), which is responsible for millions of death each year. Current therapy of TB consists of multiple expensive antibiotics and lengthy treatment, up to six months for drug-sensitive TB strains, and nine months to one year for drug-resistant TB strains. Therefore an alternative approach is urgently needed to fight this deadly disease. We propose immunotherapy which will enable to reduce length of treatment, toxic side effects, emergence of drug resistant variants, and prevent reactivation of the disease.